Table 2. The correlation between the clinical characteristics and GLRX3 expression in NPC patients.
| Cases | GLRX3 | P valuea | ||
|---|---|---|---|---|
| + | − | |||
| Gender | ||||
| Male | 44 | 29 (78.3%) | 15 (68.2%) | NS |
| Female | 15 | 8 (21.7%) | 7 (31.8%) | |
| Age (y) | ||||
| < 40 | 21 | 12 (32.4%) | 9 (40.9%) | NS |
| 40–50 | 15 | 10 (27.0%) | 5 (22.7%) | |
| ≥ 50 | 23 | 15 (40.6%) | 8 (36.4%) | |
| Non-keratinizing carcinoma | ||||
| Undifferentiated | 54 | 31 (91.2%) | 23 (92.5%) | NS |
| Differentiated | 5 | 3 (8.8%) | 2 (7.5%) | |
| Clinical stageb | ||||
| I, II | 1 | 1 (2.7%) | 0 (0.0%) | NS |
| III, IV | 58 | 36 (97.3%) | 22 (100%) | |
| Lymph node metastasis | ||||
| + | 55 | 34 (91.9%) | 21 (95.5%) | NS |
| – | 4 | 3 (8.1%) | 1 (4.5%) | |
a
by Pearson chi-square test or Fisher's exact test.
b
according to the International Union Against Cancer (UICC).
NS: not significant.